Catalyst Pharmaceutical Partners Provides Update on Research and ...
News | 12 February 2013
CORAL GABLES, FL ? February 11, 2013 -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neurological ...
Click on the link to read the full article at PharmaLive (press release) (subscription)
(This link will open in a new window)
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
